TriangleNCT00337545 · CITED IN SOURCE DOCUMENTS
Phase II Trial of RAD001 in Refractory Colorectal Cancer
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE2
- Status at capture
- COMPLETED
- Registry last update
- 2007-10-10
Single center open-label study of an oral agent (RAD001) in subjects with metastatic colorectal cancer refractory to at least 2 standard chemo/biologic regimens.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
No posted result sections were captured. Registered plans do not establish that a treatment works.
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Metastatic colorectal cancer refractory to at least 2 chemo/biologic regimens * Measurable disease * ECOG 0-2 Exclusion Criteria: * CNS disease * Chemotherapy or radiotherapy \< 4 weeks prior * Active bleeding diathesis
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- interventions
- name
- RAD001
- type
- DRUG
Study design
- allocation
- NON_RANDOMIZED
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 22
- type
- ACTUAL
Registered outcome plans (not posted results)
Full study description
- brief Summary
- Single center open-label study of an oral agent (RAD001) in subjects with metastatic colorectal cancer refractory to at least 2 standard chemo/biologic regimens.
- detailed Description
- Study is completed and closed.
Source references
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-69bd6ebad9ebeaf9d79a
- requested nct id
- NCT00337545
- primary nct id
- NCT00337545
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source file sha256
- a558d780598239714e125739b5bd8435388a575761b36a23c5dce5b640f02acf
- payload sha256
- 22caafbc6d487e5edb4e6e672cf0b9fda4a7cf6880575a77bbff06f0d929a12a
- payload
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-69bd6ebad9ebeaf9d79a
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00337545
- occurrences
- context exact
- "><ol id="_1090"><li>The use of short-course radiation therapy was evaluated in a randomized study in the Swedish Rectal Cancer Trial (<a href="/clinicaltrials/NCT00337545">NCT00337545</a>).[<a href="#cit/section_7.5">5</a>][<a href="/Common/PopUps/popDefinition.aspx?id=810017&version=HealthProfessional&language=English"
- end
- 190791
- exact text
- NCT00337545
- start
- 190780
- context exact
- 90"><li>The use of short-course radiation therapy was evaluated in a randomized study in the Swedish Rectal Cancer Trial (<a href="/clinicaltrials/NCT00337545">NCT00337545</a>).[<a href="#cit/section_7.5">5</a>][<a href="/Common/PopUps/popDefinition.aspx?id=810017&version=HealthProfessional&language=English" onclick="java
- end
- 190804
- exact text
- NCT00337545
- start
- 190793
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/nci/raw/000ed4364d31964822.html
- source file sha256
- a558d780598239714e125739b5bd8435388a575761b36a23c5dce5b640f02acf
- source json pointer
- Source null
- source kind
- nci_explicit_reference_or_link
- source record id
- Source null
- source retrieved at
- 2026-09-09T23:21:38.943216+00:00
- source string basis
- UTF-8_text_with_universal_newline_translation
- source string sha256
- 387f265965c4b56957c6f58b4d8eb54b8d5a660b7f6ef6c433eff171e69dbb77
- source title
- Rectal Cancer Treatment (PDQ®)–Health Professional Version
- source update dates
- context
- Updated: February 12, 2025
- datetime
- 2025-02-12T12:00:00Z
- display
- February 12, 2025
Preserved source evidence · Independent clinical review pending · Not medical advice